Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BWAY NASDAQ:LMAT NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$42.80+1.0%$38.34$9.22▼$45.83$2.25B1.12769,540 shs800,160 shsBWAYBrainsway$13.89-2.7%$15.07$5.11▼$17.35$571.52M1.2157,940 shs103,697 shsLMATLeMaitre Vascular$94.48+1.0%$105.55$79.00▼$118.01$2.14B0.54300,133 shs239,992 shsTMDXTransMedics Group$69.43-2.7%$88.78$60.10▼$156.00$2.47B1.911.50 million shs1.04 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+4.33%+4.87%-3.09%+48.48%+288.90%BWAYBrainsway+1.58%-10.19%-13.14%+15.58%+172.70%LMATLeMaitre Vascular+1.61%-1.51%-16.86%-13.29%+12.80%TMDXTransMedics Group+2.41%+5.22%-24.82%-45.02%-45.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$42.80+1.0%$38.34$9.22▼$45.83$2.25B1.12769,540 shs800,160 shsBWAYBrainsway$13.89-2.7%$15.07$5.11▼$17.35$571.52M1.2157,940 shs103,697 shsLMATLeMaitre Vascular$94.48+1.0%$105.55$79.00▼$118.01$2.14B0.54300,133 shs239,992 shsTMDXTransMedics Group$69.43-2.7%$88.78$60.10▼$156.00$2.47B1.911.50 million shs1.04 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+4.33%+4.87%-3.09%+48.48%+288.90%BWAYBrainsway+1.58%-10.19%-13.14%+15.58%+172.70%LMATLeMaitre Vascular+1.61%-1.51%-16.86%-13.29%+12.80%TMDXTransMedics Group+2.41%+5.22%-24.82%-45.02%-45.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.73Moderate Buy$46.508.64% UpsideBWAYBrainsway 2.75Moderate Buy$16.0015.19% UpsideLMATLeMaitre Vascular 2.75Moderate Buy$112.6019.18% UpsideTMDXTransMedics Group 2.46Hold$134.0093.00% UpsideCurrent Analyst Ratings BreakdownLatest BWAY, TMDX, LMAT, and AXGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$120.005/29/2026AXGNAxoGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026AXGNAxoGen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/26/2026TMDXTransMedics Group UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026BWAYBrainsway HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.00 ➝ $17.005/26/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$85.00 ➝ $75.005/20/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026BWAYBrainsway Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/6/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/6/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$105.00 ➝ $120.005/6/2026LMATLeMaitre Vascular Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$118.00 ➝ $127.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$225.21M10.11N/AN/A$2.79 per share15.34BWAYBrainsway$52.22M10.65$0.23 per share60.95$1.87 per share7.43LMATLeMaitre Vascular$249.60M8.65$2.93 per share32.24$17.35 per share5.45TMDXTransMedics Group$605.49M3.96$3.82 per share18.17$13.79 per share5.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A158.52N/A-13.21%-9.63%-6.26%8/4/2026 (Estimated)BWAYBrainsway$7.57M$0.3539.6929.55N/A15.68%12.28%7.75%8/12/2026 (Estimated)LMATLeMaitre Vascular$57.73M$2.7134.8628.892.6024.35%15.36%9.78%8/4/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.7819.18N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest BWAY, TMDX, LMAT, and AXGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026BWAYBrainsway$0.05$0.12+$0.07$0.06$14.63 million$15.53 million5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 million3/11/2026Q4 2025BWAYBrainsway$0.11$0.14+$0.03$0.14$14.02 million$14.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABWAYBrainswayN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.001.06%+16.05%36.90%14 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest BWAY, TMDX, LMAT, and AXGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.251%5/21/20265/21/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33BWAYBrainswayN/A3.343.04LMATLeMaitre Vascular0.4214.3212.20TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BWAYBrainsway30.11%LMATLeMaitre Vascular84.64%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.44%BWAYBrainsway19.00%LMATLeMaitre Vascular7.40%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.88 millionOptionableBWAYBrainsway12040.05 million32.44 millionNot OptionableLMATLeMaitre Vascular49022.85 million21.16 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableBWAY, TMDX, LMAT, and AXGN HeadlinesRecent News About These CompaniesTransMedics Group, Inc. (TMDX) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 4 at 7:13 PM | seekingalpha.comTransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?June 4 at 12:35 PM | zacks.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Hold" from AnalystsJune 3 at 3:05 AM | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Hold" by BrokeragesJune 2 at 2:26 AM | marketbeat.comReasons to Retain TransMedics Stock in Your Portfolio for NowMay 28, 2026 | zacks.comStifel Nicolaus Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $75.00May 26, 2026 | marketbeat.comTransMedics: Despite Earnings Miss, Growth Story Remains IntactMay 25, 2026 | seekingalpha.comTransMedics Shareholders Reelect Board and Approve Executive PayMay 21, 2026 | tipranks.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 21, 2026 | prnewswire.comTransMedics Group Signals Growth Amid Margin SqueezeMay 21, 2026 | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Gains Momentum In Healthcare SpaceMay 19, 2026 | kalkinemedia.comKTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceMay 19, 2026 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Shares Up 7.1% - Here's What HappenedMay 18, 2026 | marketbeat.comTransMedics Group (TMDX) price target decreased by 22.22% to 126.07May 14, 2026 | msn.comTransMedics Group (NASDAQ:TMDX) Reaches New 52-Week Low - Here's WhyMay 12, 2026 | marketbeat.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11, 2026 | finance.yahoo.comWall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to SellMay 9, 2026 | marketbeat.comTransMedics Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comTransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...May 8, 2026 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comTransMedics Group (TMDX) Gets a Buy from NeedhamMay 7, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBWAY, TMDX, LMAT, and AXGN Company DescriptionsAxoGen NASDAQ:AXGN$42.80 +0.41 (+0.97%) Closing price 04:00 PM EasternExtended Trading$42.47 -0.33 (-0.76%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Brainsway NASDAQ:BWAY$13.89 -0.38 (-2.66%) Closing price 04:00 PM EasternExtended Trading$14.13 +0.24 (+1.74%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.LeMaitre Vascular NASDAQ:LMAT$94.48 +0.92 (+0.98%) Closing price 04:00 PM EasternExtended Trading$94.70 +0.21 (+0.23%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.TransMedics Group NASDAQ:TMDX$69.43 -1.94 (-2.72%) Closing price 04:00 PM EasternExtended Trading$68.60 -0.83 (-1.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
